The Endocannabinoid System as a Therapeutic Target in Epilepsy

  • Krisztina Monory
  • Beat Lutz

A tightly regulated balance between excitatory and inhibitory neurotransmission is required for proper functioning of the brain in the long term. Although a strong excitatory drive is necessary for processes such as learning and memory, exaggerated levels of excitation may lead to the neuronal system getting out of control, possibly leading to pathological processes. They may range from epileptiform seizures to neurodegenerative disorders, finally resulting in a massive neuronal cell death. The present chapter will discuss the function of the endocannabinoid system in the maintenance of the balance between excitation and inhibition in the brain, and its possible therapeutic exploitation as a target against epilepsy.


Status Epilepticus GABAergic Neuron Kainic Acid Febrile Seizure Glutamatergic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ames FR, Cridland S (1986) Anticonvulsant effect of cannabidiol. S Afr Med J 69:14.PubMedGoogle Scholar
  2. Ben-Ari Y, Cossart R (2000) Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci 23:580–587.CrossRefPubMedGoogle Scholar
  3. Blair RE, Deshpande LS, Sombati S, Falenski KW, Martin BR, DeLorenzo RJ (2006) Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther 317:1072–1078.CrossRefPubMedGoogle Scholar
  4. Chen K, Baram TZ, Soltesz I (1999) Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits. Nat Med 5:888–894.CrossRefPubMedGoogle Scholar
  5. Chen K, Ratzliff A, Hilgenberg L, Gulyas A, Freund TF, Smith M, Dinh TP, Piomelli D, Mackie K, Soltesz I (2003) Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron 39:599–611.CrossRefPubMedGoogle Scholar
  6. Chen K, Neu A, Howard AL, Foldy C, Echegoyen J, Hilgenberg L, Smith M, Mackie K, Soltesz I (2007) Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci 27:46–58.CrossRefPubMedGoogle Scholar
  7. Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37–76.CrossRefPubMedGoogle Scholar
  8. Clancy CE, Kass RS (2003) Pharmacogenomics in the treatment of epilepsy. Pharmacogenomics 4:747–751.CrossRefPubMedGoogle Scholar
  9. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF (2003) Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci 23:3916–3923.PubMedGoogle Scholar
  10. Consroe PF, Wood GC, Buchsbaum H (1975) Anticonvulsant nature of marihuana smoking. JAMA 234:306–307.CrossRefPubMedGoogle Scholar
  11. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175–185.CrossRefPubMedGoogle Scholar
  12. DeLorenzo RJ, Sun DA, Deshpande LS (2005) Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintenance of epilepsy. Pharmacol Ther 105:229–266.CrossRefPubMedGoogle Scholar
  13. Deshpande LS, Blair RE, Nagarkatti N, Sombati S, Martin BR, DeLorenzo RJ (2007a) Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus. Exp Neurol 204:705–713.CrossRefPubMedGoogle Scholar
  14. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ (2007b) Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol 558:52–59.CrossRefPubMedGoogle Scholar
  15. Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ (2007c) Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett 411:11–16.CrossRefPubMedGoogle Scholar
  16. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771–784.CrossRefPubMedGoogle Scholar
  17. Ellison JM, Gelwan E, Ogletree J (1990) Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry 51:439–440.PubMedGoogle Scholar
  18. Falenski KW, Blair RE, Sim-Selley LJ, Martin BR, DeLorenzo RJ (2007) Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience 146:1232–1244.CrossRefPubMedGoogle Scholar
  19. French JA, Williamson PD, Thadani VM, Darcey TM, Mattson RH, Spencer SS, Spencer DD (1993) Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. Ann Neurol 34:774–780.CrossRefPubMedGoogle Scholar
  20. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066.PubMedGoogle Scholar
  21. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647.CrossRefGoogle Scholar
  22. Gordon E, Devinsky O (2001) Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 42:1266–1272.CrossRefPubMedGoogle Scholar
  23. Iversen LL (2000) The Science of Marijuana. Oxford: Oxford University Press.Google Scholar
  24. Keeler MH, Reifler CB (1967) Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst 28:474–475.PubMedGoogle Scholar
  25. Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR (2001) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42:321–327.CrossRefPubMedGoogle Scholar
  26. LaRoche SM, Helmers SL (2004) The new antiepileptic drugs: scientific review. JAMA 291:605–614.CrossRefPubMedGoogle Scholar
  27. Leite JP, Cavalheiro EA (1995) Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 20:93–104.CrossRefPubMedGoogle Scholar
  28. Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ (2006) Arachidonyl-2′-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 547:65–74.CrossRefPubMedGoogle Scholar
  29. Lutz B (2004) On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 68:1691–1698.CrossRefPubMedGoogle Scholar
  30. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101–122.CrossRefPubMedGoogle Scholar
  31. Mackie K, Stella N (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8:E298–E306.PubMedGoogle Scholar
  32. Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213–4225.CrossRefPubMedGoogle Scholar
  33. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84–88.CrossRefPubMedGoogle Scholar
  34. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564.CrossRefPubMedGoogle Scholar
  35. Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535–550.CrossRefPubMedGoogle Scholar
  36. McCormick DA, Contreras D (2001) On the cellular and network bases of epileptic seizures. Annu Rev Physiol 63:815–846.CrossRefPubMedGoogle Scholar
  37. Mechoulam R (1986) The pharmacohistory of Cannabis sativa. In: Mechoulam R (ed.), Cannabinoids as Therapeutic Agents. Boca Raton, FL: CRC Press, pp. 1–19.Google Scholar
  38. Mechoulam R, Lichtman AH (2003) Neuroscience. Stout guards of the central nervous system. Science 302:65–67.CrossRefPubMedGoogle Scholar
  39. Mello LE, Cavalheiro EA, Tan AM, Kupfer WR, Pretorius JK, Babb TL, Finch DM (1993) Circuit mechanisms of seizures in the pilocarpine model of chronic epilepsy: cell loss and mossy fiber sprouting. Epilepsia 34:985–995.CrossRefPubMedGoogle Scholar
  40. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455–466.CrossRefPubMedGoogle Scholar
  41. Ng SK, Brust JC, Hauser WA, Susser M (1990) Illicit drug use and the risk of new-onset seizures. Am J Epidemiol 132:47–57.PubMedGoogle Scholar
  42. Noebels JL (2003) The biology of epilepsy genes. Annu Rev Neurosci 26:599–625.CrossRefPubMedGoogle Scholar
  43. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed.), Cannabinoids. New York: Kluwer Academic/Plenum Publishers, pp. 32–42.Google Scholar
  44. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873–884.CrossRefPubMedGoogle Scholar
  45. Ratzliff AH, Santhakumar V, Howard A, Soltesz I (2002) Mossy cells in epilepsy: rigor mortis or vigor mortis? Trends Neurosci 25:140–144.CrossRefPubMedGoogle Scholar
  46. Schauwecker PE, Steward O (1997) Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci USA 94:4103–4108.CrossRefPubMedGoogle Scholar
  47. Schuchmann S, Schmitz D, Rivera C, Vanhatalo S, Salmen B, Mackie K, Sipila ST, Voipio J, Kaila K (2006) Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis. Nat Med 12:817–823.CrossRefPubMedGoogle Scholar
  48. Schwenkreis P, Tegenthoff M (2003) Therapeutic use of cannabinoids in neurology. Schmerz 17:367–373.CrossRefPubMedGoogle Scholar
  49. Sheerin AH, Zhang X, Saucier DM, Corcoran ME (2004) Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia 45:1184–1188.CrossRefPubMedGoogle Scholar
  50. Shen M, Piser TM, Seybold VS, Thayer SA (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322–4334.PubMedGoogle Scholar
  51. Shinnar S, Glauser TA (2002) Febrile seizures. J Child Neurol 17:S44–S52.CrossRefPubMedGoogle Scholar
  52. Straiker A, Mackie K (2007) Metabotropic suppression of excitation in murine autaptic hippocampal neurons. J Physiol 578:773–785.CrossRefPubMedGoogle Scholar
  53. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ (2003) The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307:129–137.CrossRefPubMedGoogle Scholar
  54. Wettschureck N, van der SM, Tsubokawa H, Krestel H, Moers A, Petrosino S, Schutz G, Di Marzo V, Offermanns S (2006) Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation. Mol Cell Biol 26:5888–5894.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Krisztina Monory
  • Beat Lutz
    • 1
  1. 1.Institute of Physiological Chemistry and PathobiochemistryJohannes Gutenberg-University MainzMainzGermany

Personalised recommendations